NICE now recommends Celgene's Otezla

The U.K.'s NICE released draft guidance recommending Otezla apremilast from Celgene Corp. (NASDAQ:CELG) to treat chronic plaque psoriasis. It recommended against the therapy's use in final guidance issued last September (see BioCentury Extra, September 3, 2015).

In the new guidance, NICE recommended Otezla as an option to treat severe chronic plaque psoriasis that has not responded to systemic therapy, or if systemic therapy is contraindicated or not tolerated. The recommendation is contingent on an undisclosed discount included in Celgene's patient access scheme. ...